Peginterferon-α-2b/ribavirin
1
Reactions 1476, p27 - 2 Nov 2013 S Peginterferon-α-2b/ribavirin Chronic subdural haematoma in an elderly patient: case report A 70-year-old man with hepatitis C developed a chronic subdural haematoma during treatment with peginterferon- α-2b and ribavirin. In November 2010, the man started receiving peginterferon- α-2b 100 µg/week and ribavirin 800 mg/day [routes not stated]. After 18 weeks, his HCV RNA titer became negative. As he was judged to have a late viral response, he was scheduled to continue peginterferon-α-2b and ribavirin for 72 weeks. However, after 51 weeks he developed a headache and an unsteady gait, and exhibited Barre’s sign on his right foot. CT scanning revealed a subdural haematoma on his left side with a mass effect. The man underwent neurosurgery; peginterferon-α-2b and ribavirin were withdrawn. His platelet count and prothrombin time at that point were within the normal range; he did not have a history of direct head trauma. There were no neurological sequelae. Author comment: "[S]ince ICH [intracerebral haemorrhage] is a rare and life-threatening condition, it should be well publicized as a complication of combination therapy, regardless of the type of IFN alfa-2b used . . . there have been only a few cases of CSDH [chronic subdural haematoma] occurring in chronic hepatitis C patients receiving PEG-IFN [peginterferon] + RBV [ribavirin] therapy". Goto T, et al. A chronic subdural hematoma in a patient receiving combination therapy with pegylated interferon alfa-2b and ribavirin for chronic hepatitis C. Internal Medicine 52: 2057-2060, No. 18, 2013. Available from: URL: http:// dx.doi.org/10.2169/internalmedicine.52.0791 - Japan 803095077 1 Reactions 2 Nov 2013 No. 1476 0114-9954/13/1476-0001/$14.95 Adis © 2013 Springer International Publishing AG. All rights reserved
Transcript of Peginterferon-α-2b/ribavirin
Reactions 1476, p27 - 2 Nov 2013
SPeginterferon-α-2b/ribavirin
Chronic subdural haematoma in an elderly patient:case report
A 70-year-old man with hepatitis C developed a chronicsubdural haematoma during treatment with peginterferon-α-2b and ribavirin.
In November 2010, the man started receiving peginterferon-α-2b 100 µg/week and ribavirin 800 mg/day [routes notstated]. After 18 weeks, his HCV RNA titer became negative. Ashe was judged to have a late viral response, he was scheduledto continue peginterferon-α-2b and ribavirin for 72 weeks.However, after 51 weeks he developed a headache and anunsteady gait, and exhibited Barre’s sign on his right foot. CTscanning revealed a subdural haematoma on his left side with amass effect.
The man underwent neurosurgery; peginterferon-α-2b andribavirin were withdrawn. His platelet count and prothrombintime at that point were within the normal range; he did nothave a history of direct head trauma. There were noneurological sequelae.
Author comment: "[S]ince ICH [intracerebralhaemorrhage] is a rare and life-threatening condition, itshould be well publicized as a complication of combinationtherapy, regardless of the type of IFN alfa-2b used . . . therehave been only a few cases of CSDH [chronic subduralhaematoma] occurring in chronic hepatitis C patientsreceiving PEG-IFN [peginterferon] + RBV [ribavirin] therapy".Goto T, et al. A chronic subdural hematoma in a patient receiving combinationtherapy with pegylated interferon alfa-2b and ribavirin for chronic hepatitis C.Internal Medicine 52: 2057-2060, No. 18, 2013. Available from: URL: http://dx.doi.org/10.2169/internalmedicine.52.0791 - Japan 803095077
1
Reactions 2 Nov 2013 No. 14760114-9954/13/1476-0001/$14.95 Adis © 2013 Springer International Publishing AG. All rights reserved
